Literature DB >> 7487230

Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: a community-based study.

F Z al-Faleh1, S Ramia, M Arif, E A Ayoola, R S al-Rashed, M al-Jeffry, A Hossain, M el-Hazmi.   

Abstract

The seroprevalence of antibody to hepatitis C virus (anti-HCV) and the possible modes of transmission of HCV were investigated in Gizan, southern Saudi Arabia. The sample size chosen to give an adequate estimate of the seroprevalence, about 1500, was based on the assumption that 5% of the population in Gizan were anti-HCV-positive. Sera from 1482 subjects (705 males, 777 females; aged > or = 10 years) were initially screened for anti-HCV using a commercial, ubiquitin-based enzyme immunoassay. Repeatedly reactive sera were confirmed positive using second-generation immunoassays. Serum samples were also tested by ELISA for hepatitis B surface antigen (HbsAg) and antibodies to this antigen and to the hepatitis B core antigen. Of the subjects tested, 27 (1.8%) were anti-HCV-positive. Exposure to HCV was generally similar in both sexes, age-prevalence curves for anti-HCV peaking in males aged > 49 years (6.2%) and in females aged 40-49 years (5.0%). In the youngest subjects, those aged 10-19 years, the HbsAg carrier rate was significantly higher in males (10.4%) than in females (3.6%). Exposure to the hepatitis B virus was similar in both sexes (31.0% in males v. 28.6% in females). Some 7.4% and 14.8% of the 27 anti-HCV-positive cases had histories of schistosomiasis and blood transfusion, respectively. The corresponding values for the 1455 anti-HCV-negative cases investigated, 1.1% for schistosomiasis and 3.5% for blood transfusion, were much lower. The spouses and other family members of eight anti-HCV-positive index cases were investigated but none was anti-HCV-positive.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7487230     DOI: 10.1080/00034983.1995.11812972

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  6 in total

1.  Laboratory diagnosis of viral hepatitis C: The Sultan Qaboos University Hospital experience.

Authors:  Said H S Al Dhahry; Jameel C Nograles; Situsekara M W W B Rajapakse; Fadhila S S Al Toqi; Geraldine Z Kaminski
Journal:  J Sci Res Med Sci       Date:  2003-08

2.  Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods.

Authors:  P M Schneeberger; I Keur; W van der Vliet; K van Hoek; H Boswijk; A M van Loon; W C van Dijk; R H Kauffmann; W Quint; L J van Doorn
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

3.  Epidemiology of hepatitis C virus (HCV) infection.

Authors:  Theodore Sy; M Mazen Jamal
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

4.  SASLT practice guidelines: management of hepatitis C virus infection.

Authors:  Abdullah S Alghamdi; Faisal M Sanai; Mona Ismail; Hamdan Alghamdi; Khalid Alswat; Adel Alqutub; Ibrahim Altraif; Hemant Shah; Faleh Z Alfaleh
Journal:  Saudi J Gastroenterol       Date:  2012-09       Impact factor: 2.485

5.  Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.

Authors:  Abdulrahman A Aljumah; Faisal Abaalkhail; Hamad Al-Ashgar; Abdullah Assiri; Mohamed Babatin; Faleh Al Faleh; Abdullah Alghamdi; Raafat Al-Hakeem; Almoataz Hashim; Adel Alqutub; Homie Razavi; Faisal M Sanai; Khalid Al-Swat; Jonathan Schmelzer; Ibrahim Altraif
Journal:  Saudi J Gastroenterol       Date:  2016 Jul-Aug       Impact factor: 2.485

6.  Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Authors:  Hamad Al Ashgar; Ahmed Helmy; Mohamed Q Khan; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Abdullah Alshehri; Abdullah Al Kalbani; Khalid Al Swat; Salim Dahab; Naser Elkum; Mohammed Al Fadda
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.